Reviews and feature articleSevere asthma: Advances in current management and future therapy
Section snippets
SMART strategies
Several studies have shown that in patients with moderate-to-severe asthma, there is an improvement in asthma control and significant reduction in severe exacerbations if a budesonide/formoterol combination inhaler is used as a reliever instead of a short-acting β2-agonist, whereas maintenance therapy with budesonide/formoterol is administered twice daily as usual.6 This strategy is now known as single inhaler maintenance and reliever therapy (SMART) and could presumably be used with any
New corticosteroids
Several ICSs are currently available for clinical use, and all have similar clinical efficacy, but there are differences in pharmacodynamic properties so that systemic exposure might differ. Because patients with severe asthma might require higher doses of ICSs, there is an advantage in developing systemic corticosteroids with fewer systemic side effects. Ciclesonide is a recently developed ICS and appears to have the least systemic effects and local side effects because the prodrug is
New bronchodilators
Bronchodilators play an important role in reducing symptoms in patients with severe asthma, and currently, LABAs are the bronchodilators of choice, usually given in combination with ICSs in a fixed-dose inhaler. Bronchodilators are essential in the management of asthma because they relieve and prevent bronchoconstriction. There have been several advances in the development of bronchodilators for the treatment of severe asthma.
Anti-IgE
Omalizumab is the only novel therapy that has specifically been approved for the treatment of severe asthma. Omalizumab is an mAb that binds the Fc portion of IgE and thus prevents activating its high-affinity IgE receptor (FcεRI) on mast cells, basophils, and dendritic cells, as well as a low-affinity receptor (FcεRII) expressed on several immune and inflammatory cells, including macrophages, eosinophils, and T and B lymphocytes. Numerous clinical trials have demonstrated the clinical efficacy
Targeting inflammatory mediators
More than 100 mediators are involved in the complex inflammation of asthma, making it unlikely that blocking the synthesis or receptor for a single mediator could be very effective. ICSs are highly effective in suppressing the synthesis of multiple inflammatory mediators, but in patients with severe asthma, they appear to be less effective, making it possible that adding a mediator antagonist to high doses of ICSs might be beneficial. In addition, the inflammation seen in some patients with
Broad-spectrum anti-inflammatory treatments
The fact that the symptoms of patients with severe asthma might not be controlled by high doses of ICSs plus LABAs and sometimes even oral corticosteroids has prompted a search for alternative anti-inflammatory therapies that can be added to existing therapies to provide additional control. In addition, inflammation in some patients with severe asthma is predominantly neutrophilic so that inhibitors of neutrophilic inflammation are needed, and corticosteroids are poorly effective against
Mast cell inhibitors
Mast cell activation is important as a driving mechanism in some patients with severe asthma.53 There are several approaches to inhibiting mast cell activation (Fig 3),5 and anti-IgE has already been shown to be of value in the treatment of some patients with severe asthma. Stem cell factor is a key regulator of mast cell survival in the airways and acts through the receptor c-Kit on mast cells.110 Plasma concentrations of stem cell factor are increased in patients with severe asthma.111
The problem of corticosteroid resistance
Resistance to the anti-inflammatory effects of corticosteroids might be an important factor in determining asthma severity. Several molecular mechanisms have now been described to account for corticosteroid resistance in asthmatic patients, including activation of p38 MAPK activity (as described above), increased expression of an alternatively spliced variant of the glucocorticoid receptor GRβ, increased production of macrophage migratory inhibitory factor (MIF), and reduced expression of HDAC2.
Macrolides
There is evidence that some patients with severe asthma are chronically infected with atypical bacteria, such as Mycoplasma pneumoniae and Chlamydia pneumoniae.133 In patients with infection confirmed by means of PCR and culture, there was a significant improvement in FEV1 after a 6-week course of clarythromycin.134 However, in a larger trial of patients with poorly controlled asthma, treatment with clarithromycin over a 16-week period did not produce any clinically meaningful improvement in
Bronchial thermoplasty
Bronchial thermoplasty delivers controlled thermal energy to the bronchial wall to selectively reduce the amount of airway smooth muscle and has been studied in patients with severe asthma. It is usually administered as 3 outpatient bronchoscopic procedures separated by 3 weeks. In a large controlled trial of almost 200 patients with severe asthma, bronchial thermoplasty compared with a sham procedure produced a small improvement in asthma-specific quality-of-life scores (although this was far
Future directions
It is now becoming clear that there are several distinct phenotypes of severe asthma and that these might require different therapeutic approaches. For example, patients whose symptoms were not controlled on maximal inhaled therapies that have high sputum eosinophilia and frequent exacerbations might benefit from anti–IL-5 therapy with mepolizumab or reslizumab. By contrast, neutrophilic asthma might respond to anti-inflammatory therapies that target neutrophilic inflammation, including PDE4
References (144)
New drugs for asthma: is there any progress?
Trends Pharmacol Sci
(2010)- et al.
Rapid anti-inflammatory effect of inhaled ciclesonide in asthma: a randomised, placebo-controlled study
Chest
(2008) - et al.
Rescue treatment in asthma. More than as-needed bronchodilation
Chest
(2009) - et al.
New asthma drugs: small molecule inhaled corticosteroids
Curr Opin Pharmacol
(2010) Selective glucocorticoid receptor modulators
J Steroid Biochem Mol Biol
(2010)Safety of long-acting beta-agonists: are new data really required?
Chest
(2009)- et al.
Alternative mechanisms for tiotropium
Pulm Pharmacol Ther
(2009) - et al.
Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro
Respir Med
(2007) - et al.
Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial
J Allergy Clin Immunol
(2011) - et al.
Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma
J Allergy Clin Immunol
(2011)
Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review
Chest
Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma
J Allergy Clin Immunol
New molecular targets for the treatment of neutrophilic diseases
J Allergy Clin Immunol
Addition of an anti-leukotriene to therapy in chronic severe asthma in a clinic setting: a double-blind, randomised, placebo-controlled study
Lancet
The role of leukotriene B(4) in allergic diseases
Allergol Int
5-Oxo-ETE and the OXE receptor
Prostaglandins Other Lipid Mediat
Defective glucocorticoid receptor nuclear translocation and altered histone acetylation patterns in glucocorticoid-resistant patients
J Allergy Clin Immunol
Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
Lancet
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness and the late asthmatic response
Lancet
Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome
J Allergy Clin Immunol
Airway wall expression of OX40/OX40L and interleukin-4 in asthma
Chest
PDE4-inhibitors: a novel, targeted therapy for obstructive airways disease
Pulm Pharmacol Ther
Keynote review: phosphodiesterase-4 as a therapeutic target
Drug Discov Today
Kinase inhibitors and airway inflammation
Eur J Pharmacol
p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma
J Allergy Clin Immunol
Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study
BMC Pulm Med
Suboptimal asthma control: prevalence, detection and consequences in general practice
Eur Respir J
The prevalence of nonadherence in difficult asthma
Am J Respir Crit Care Med
“Refractory” eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids
Am J Respir Crit Care Med
Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children
Cochrane Database Syst Rev
Scientific rationale for using a single inhaler for asthma control
Eur Respir Dis
Clinical pharmacokinetic and pharmacodynamic profile of inhaled ciclesonide
Clin Pharmacokinet
The small airways and distal lung compartment in asthma and COPD: a time for reappraisal
Allergy
Glucocorticosteroids: current and future directions
Br J Pharmacol
Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects
Proc Natl Acad Sci U S A
The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis
Am J Respir Crit Care Med
Beta(2)-adrenoceptor agonists: current and future direction
Br J Pharmacol
A role for sensory nerves in the late asthmatic response
Thorax
The epithelial cholinergic system of the airways
Histochem Cell Biol
Non-bronchodilating mechanisms of tiotropium prevent airway hyperreactivity in a guinea pig model of allergic asthma
Br J Pharmacol
Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma
Clin Exp Allergy
Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison
Eur Respir J
Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD
Eur Respir J
Additive role of tiotropium in severe asthmatics and Arg16Gly in ADRB2 as a potential marker to predict response
Allergy
Tiotropium bromide step-up therapy for adults with uncontrolled asthma
N Engl J Med
Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease
Expert Opin Investig Drugs
Triple inhalers for obstructive airways disease: will they be useful?
Expert Rev Respir Med
Muscarinic antagonist-beta-adrenergic agonist dual pharmacology molecules as bronchodilators: a patent review
Expert Opin Ther Pat
Bronchodilation by an inhaled VPAC(2) receptor agonist in patients with stable asthma
Thorax
Bitter taste receptors on airway smooth muscle bronchodilate by localized calcium signaling and reverse obstruction
Nat Med
Cited by (0)
Disclosure of potential conflict of interest: P. J. Barnes receives research support from GlaxoSmithKline, AstraZeneca, Novartis, Boehringer Ingelheim, and Pfizer.